These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11190486)

  • 1. Current and potential therapeutic uses of lanthanide radioisotopes.
    Cutler CS; Smith CJ; Ehrhardt GJ; Tyler TT; Jurisson SS; Deutsch E
    Cancer Biother Radiopharm; 2000 Dec; 15(6):531-45. PubMed ID: 11190486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149.
    Allen BJ; Blagojevic N
    Nucl Med Commun; 1996 Jan; 17(1):40-7. PubMed ID: 8692472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolanthanides in nuclear medicine.
    Rösch F; Forssell-Aronsson E
    Met Ions Biol Syst; 2004; 42():77-108. PubMed ID: 15206100
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (99m)Tc and (111)In-labeling of small biomolecules: bifunctional chelators and related coordination chemistry.
    Chakraborty S; Liu S
    Curr Top Med Chem; 2010; 10(11):1113-34. PubMed ID: 20388113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
    Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
    Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Techniques for loading technetium-99m and rhenium-186/188 radionuclides into pre-formed liposomes for diagnostic imaging and radionuclide therapy.
    Goins B; Bao A; Phillips WT
    Methods Mol Biol; 2010; 606():469-91. PubMed ID: 20013416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Achievements and perspectives of radioisotope diagnosis of malignant tumors (according to materials in the "Journal of Nuclear Medicine", 1974)].
    Zherbin EA; Fateeva MN
    Med Radiol (Mosk); 1976 Jan; 21(1):79-84. PubMed ID: 59300
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents.
    Harris TD; Kalogeropoulos S; Nguyen T; Dwyer G; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Robinson S; Lazewatsky J; Barrett J
    Bioconjug Chem; 2006; 17(5):1294-313. PubMed ID: 16984141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
    Maecke HR; Reubi JC
    J Nucl Med; 2011 Jun; 52(6):841-4. PubMed ID: 21571797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
    Mishra G; Panwar P; Mishra AK
    Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
    Wessels BW; Rogus RD
    Med Phys; 1984; 11(5):638-45. PubMed ID: 6503879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of functionalised HP-DO3A chelating agents for conjugation to biomolecules.
    Barge A; Cappelletti E; Cravotto G; Ferrigato A; Lattuada L; Marinoni F; Tei L
    Org Biomol Chem; 2009 Sep; 7(18):3810-6. PubMed ID: 19707687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (99m)Tc Auger electrons for targeted tumour therapy: a review.
    Tavares AA; Tavares JM
    Int J Radiat Biol; 2010 Apr; 86(4):261-70. PubMed ID: 20353336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
    Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Radioactive isotopes in the diagnosis and therapy of tumors].
    Gazzera G; Petruzzelli C; Remonda G; Pugnani M; Sacchi L; Cereser M
    Ann Osp Maria Vittoria Torino; 1979; 22(7-12):181-337. PubMed ID: 262620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
    Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROPERTIES, USES, RADIOCHEMICAL PURITY AND CALIBRATION OF TC-99M.
    SMITH EM
    J Nucl Med; 1964 Nov; 5():871-82. PubMed ID: 14247783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.